Figure 2: Proliferation of reprogrammed hepatocytes (Fah−/−/Hpd−/−) rescues HT-I lethality. | Nature Communications

Figure 2: Proliferation of reprogrammed hepatocytes (Fah−/−/Hpd−/−) rescues HT-I lethality.

From: Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia

Figure 2

(a) Co-staining for EdU (red) and HPD (green), counterstain is 4,6-diamidino-2-phenylindole (blue). Proliferating, EdU-positive cells are HPD-negative. Kaplan–Meier survival curves (b) and body weights (c, mean±s.d.) of tyrosinemic animals treated with either Cas9 only or both Cas9 and gRNA1/3 (each group N=5). Time after withdrawal from nitisinone (7 days after injection) is shown. (d) Range of repopulation by reprogrammed hepatocytes (Fah−/−/Hpd−/−) 8 weeks after injection. The mouse on the right has an almost complete repopulation by edited hepatocytes (>99%) and only a few non-edited (Fah−/−/Hpd+/+) hepatocytes are visible in the whole section. Black squares are amplified in the images below. Scale bar, 50 μm.

Back to article page